Abstract
Generalized pustular psoriasis (GPP) is a rare, but severe form of psoriasis characterized by febrile illness, sudden eruption of erthema, sterile pustules, sever psoriatic arthritis. We report a case of 21 year old female patient having recalcitrant GPP, resistant to usual line of treatment who has been successfully treated with secukinumab. Treatment of GPP include steroids, acitretin or methotrexate, which still comprise the first-line treatment. Secukinumab is a first in class, recombinant, fully human monoclonal antibody that targets and blocks the actions of Interleukin 17-A (IL-17A). It is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis and rheumatoid arthritis from 2015. The recalcitrant pustular psoriasis responded well to secukinumab with disappearance of steroid induce complications, after 3 doses and no recurrence during follow-up period. Keywords: Impetigo herpetiformis, Pustular psoriasis, Secukinumab, IL17, Biologics.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
